987 related articles for article (PubMed ID: 21734724)
1. Cyclin D as a therapeutic target in cancer.
Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL
Nat Rev Cancer; 2011 Jul; 11(8):558-72. PubMed ID: 21734724
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
3. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Gong X; Litchfield LM; Webster Y; Chio LC; Wong SS; Stewart TR; Dowless M; Dempsey J; Zeng Y; Torres R; Boehnke K; Mur C; Marugán C; Baquero C; Yu C; Bray SM; Wulur IH; Bi C; Chu S; Qian HR; Iversen PW; Merzoug FF; Ye XS; Reinhard C; De Dios A; Du J; Caldwell CW; Lallena MJ; Beckmann RP; Buchanan SG
Cancer Cell; 2017 Dec; 32(6):761-776.e6. PubMed ID: 29232554
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix.
Topacio BR; Zatulovskiy E; Cristea S; Xie S; Tambo CS; Rubin SM; Sage J; Kõivomägi M; Skotheim JM
Mol Cell; 2019 May; 74(4):758-770.e4. PubMed ID: 30982746
[TBL] [Abstract][Full Text] [Related]
5. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
Laman H; Funes JM; Ye H; Henderson S; Galinanes-Garcia L; Hara E; Knowles P; McDonald N; Boshoff C
EMBO J; 2005 Sep; 24(17):3104-16. PubMed ID: 16096642
[TBL] [Abstract][Full Text] [Related]
6. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
7. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes.
Kozar K; Sicinski P
Cell Cycle; 2005 Mar; 4(3):388-91. PubMed ID: 15738651
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
10. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
11. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6.
Fiaschi-Taesch NM; Salim F; Kleinberger J; Troxell R; Cozar-Castellano I; Selk K; Cherok E; Takane KK; Scott DK; Stewart AF
Diabetes; 2010 Aug; 59(8):1926-36. PubMed ID: 20668294
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclins and cdks throughout murine carcinogenesis.
Yerly-Motta V; Contassot E; Pavy JJ; Tiberghien P; Hervé P
Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1217-28. PubMed ID: 10643971
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
16. Lineage specific composition of cyclin D-CDK4/CDK6-p27 complexes reveals distinct functions of CDK4, CDK6 and individual D-type cyclins in differentiating cells of embryonic origin.
Bryja V; Pacherník J; Vondráček J; Souček K; Čajánek L; Horvath V; Holubcová Z; Dvořák P; Hampl A
Cell Prolif; 2008 Dec; 41(6):875-893. PubMed ID: 19040567
[TBL] [Abstract][Full Text] [Related]
17. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
Lee YM; Sicinski P
Cell Cycle; 2006 Sep; 5(18):2110-4. PubMed ID: 16969111
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.
Molenaar JJ; Ebus ME; Koster J; van Sluis P; van Noesel CJ; Versteeg R; Caron HN
Cancer Res; 2008 Apr; 68(8):2599-609. PubMed ID: 18413728
[TBL] [Abstract][Full Text] [Related]
20. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.
Bates S; Bonetta L; MacAllan D; Parry D; Holder A; Dickson C; Peters G
Oncogene; 1994 Jan; 9(1):71-9. PubMed ID: 8302605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
